Cortexyme (CRTX) News Today $1.32 +0.05 (+3.94%) As of 04/2/2025 Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsInsider TradesTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Cortexyme (NASDAQ:CRTX) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?Cortexyme (NASDAQ:CRTX) Stock Price Passes Above 200 Day Moving Average - Time to Sell?February 8, 2025 | marketbeat.comCortexyme (NASDAQ:CRTX) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedCortexyme (NASDAQ:CRTX) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?January 23, 2025 | marketbeat.comCortexyme (NASDAQ:CRTX) Shares Cross Above 200-Day Moving Average - Here's WhyCortexyme (NASDAQ:CRTX) Shares Pass Above 200-Day Moving Average - What's Next?January 15, 2025 | marketbeat.comCortexyme (NASDAQ:CRTX) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?Cortexyme (NASDAQ:CRTX) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedJanuary 7, 2025 | marketbeat.comCortexyme (NASDAQ:CRTX) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell?Cortexyme (NASDAQ:CRTX) Stock Passes Above Two Hundred Day Moving Average - What's Next?December 28, 2024 | marketbeat.comCortexyme (NASDAQ:CRTX) Stock Price Crosses Above 200-Day Moving Average - Here's What HappenedCortexyme (NASDAQ:CRTX) Stock Passes Above Two Hundred Day Moving Average - Here's WhyDecember 20, 2024 | marketbeat.comCortexyme (NASDAQ:CRTX) Trading Up 4.1% - Still a Buy?Cortexyme (NASDAQ:CRTX) Shares Up 4.1% - What's Next?December 12, 2024 | marketbeat.comCortexyme (NASDAQ:CRTX) Shares Pass Above 200 Day Moving Average - Here's What HappenedCortexyme (NASDAQ:CRTX) Share Price Passes Above 200 Day Moving Average - Here's What HappenedNovember 9, 2024 | marketbeat.comCrism Thera Regulatory NewsAugust 4, 2024 | lse.co.ukCortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.comAugust 1, 2022 | marketscreener.comCortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.comJuly 27, 2022 | marketscreener.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business WireJuly 27, 2022 | businesswire.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business WireJuly 27, 2022 | businesswire.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.comJuly 27, 2022 | marketscreener.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo FinanceJuly 27, 2022 | finance.yahoo.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588July 27, 2022 | finance.yahoo.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022July 27, 2022 | finance.yahoo.comCortexyme (CRTX) Announces Resignation of EVP of Research and Development - StreetInsider.comJuly 22, 2022 | streetinsider.comBragar Eagel & Squire, PC Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm - GuruFocus.comJune 26, 2022 | gurufocus.comCortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus In - BenzingaJune 21, 2022 | benzinga.comCortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment - NasdaqJune 21, 2022 | nasdaq.comCortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsJune 21, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of Directors - Business WireJune 13, 2022 | businesswire.comCortexyme Appoints June Bray to its Board of Directors - Yahoo FinanceJune 13, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of DirectorsJune 13, 2022 | finance.yahoo.comCortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer - Marketscreener.comJune 11, 2022 | marketscreener.comCortexyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.comJune 10, 2022 | marketscreener.comCortexyme Successfully Completes Acquisition of Novosteo - Business WireMay 22, 2022 | businesswire.comThis Is the Worst Type of Credit Card for Most Consumers - NasdaqMay 20, 2022 | nasdaq.comPPG Showcases Innovations in Paints, Coatings, Specialty Materials That Enhance Sustainability, Efficiency, Mobility - Yahoo FinanceMay 20, 2022 | finance.yahoo.comCortexyme : Completion of Acquisition or Disposition of Assets - Form 8-K - Marketscreener.comMay 20, 2022 | marketscreener.comCortexyme Successfully Completes Acquisition of Novosteo - Yahoo FinanceMay 20, 2022 | finance.yahoo.comCortexyme Appoints Dr. Philip Low to Its Board of DirectorsMay 20, 2022 | finance.yahoo.comPre-market Movers: EBET, AFRM, CELU, FIGS, LLAP… - NasdaqMay 13, 2022 | nasdaq.comCortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases - Yahoo FinanceMay 12, 2022 | finance.yahoo.comCortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic DiseasesMay 12, 2022 | finance.yahoo.comForm 10-Q Cortexyme, Inc. For: Mar 31 - StreetInsider.comMay 11, 2022 | streetinsider.comCortexyme Announces Agreement to Acquire Novosteo - StreetInsider.comMay 11, 2022 | streetinsider.comTuesday Digest: Prologis attempts hostile buyout of Duke; Salesforce's latest buy - San Francisco Business Times - The Business JournalsMay 10, 2022 | bizjournals.comCortexyme Announces Agreement to Acquire NovosteoMay 10, 2022 | finance.yahoo.comBragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the FirmMay 6, 2022 | benzinga.comIs Cortexyme (NASDAQ:CRTX) In A Good Position To Deliver On Growth Plans?May 6, 2022 | finance.yahoo.comBragar Eagel & Squire, PC Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the Firm - GuruFocus.comMay 3, 2022 | gurufocus.comThe Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Appl - BenzingaMay 3, 2022 | benzinga.comCortexyme Announces Further Layoffs, Chief Medical Officer LeavesMay 3, 2022 | benzinga.comCORTEXYME, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K) - Marketscreener.comMay 3, 2022 | marketscreener.comBragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the FirmMay 1, 2022 | benzinga.comCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - BenzingaApril 28, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Cortexyme, Corcept, RBB, and Verra and Encourages Investors to Contact the FirmApril 25, 2022 | benzinga.comThinking about buying stock in Cortexyme, Borqs Technologies, Sundial Growers, Nokia, or Nordic American Tanker? - PR NewswireApril 25, 2022 | prnewswire.com Remove Ads Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CRTX Media Mentions By Week CRTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRTX News Sentiment▼0.000.61▲Average Medical News Sentiment CRTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRTX Articles This Week▼00▲CRTX Articles Average Week Remove Ads Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Omnicell News HealthStream News Veradigm News Neumora Therapeutics News Protara Therapeutics News Inhibikase Therapeutics News 4D Molecular Therapeutics News Innate Pharma News Sangamo Therapeutics News Kodiak Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRTX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRTX Stock Free CRTX Stock Alerts